The Role of Anticoagulation in COVID-19-Induced Hypercoagulability.
Curr Cardiol Rep
; 22(7): 53, 2020 06 17.
Article
in English
| MEDLINE | ID: covidwho-601043
ABSTRACT
PURPOSE OF REVIEW We aim to provide a comprehensive analysis of hypercoagulability in individuals affected by COVID-19. Our goal is to describe the hypercoagulable state related to the infection and provide guidance regarding the possible benefits of anti-coagulation with the support of evidence from current literature. RECENT FINDINGS:
The incidence of thrombotic disease in individuals affected by COVID-19 is reported as high as 31%. A significant mortality benefit has been observed with the use of therapeutic anticoagulation in high-risk individuals. Literature supports the use of scoring systems, such as the sepsis-induced coagulopathy score, to risk-stratify individuals who might benefit from anticoagulation. COVID-19-induced hypercoagulability has been demonstrated to play a significant role in overall COVID-19 outcomes. Current literature shows promising evidence with the use of therapeutic anticoagulation in high-risk individuals. Further studies are needed to better analyze the risks and benefits of anticoagulation in this specific patient population.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Critical Illness
/
Thrombophilia
Type of study:
Observational study
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Curr Cardiol Rep
Journal subject:
Cardiology
Year:
2020
Document Type:
Article
Affiliation country:
S11886-020-01328-8
Similar
MEDLINE
...
LILACS
LIS